Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | PHASE1 | COMPLETED | 41 | — | — | Nov 24, 2020 | May 12, 2023 | May 17, 2023 | 1 | Germany |
Safety of a single dose of CDX-0159 as determined by adverse events
| Arm | Type | Description |
|---|---|---|
| CDX-0159 | EXPERIMENTAL | 20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159 |
| Name | Type | Description |
|---|---|---|
| CDX-0159 | DRUG | Administered intravenously |
Key Inclusion Criteria: 1. Diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria which does not respond to antihistamines * Diagnosis for ≥ 3 months; symptoms of both hive (wheal) and itch/burning/painful sensation despite concurrent use of anti-histamines ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 10 | PHASE3 | LOU064, Remibrutinib, Omalizumab, Dupilumab |
| Celldex Therapeutics, Inc. | CLDX | 4 | PHASE3 | barzolvolimab, Barzolvolimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| ARS Pharmaceuticals, Inc. | SPRY | 1 | PHASE2 | epinephrine |
| Jasper Therapeutics, Inc. | JSPR | 2 | PHASE2 | Briquilimab |
| Blueprint Medicines Corporation | BPMC | 1 | PHASE2 | BLU-808 |
| Azitra Inc. | AZTR | 1 | PHASE1 | ATR04-484, Vehicle |
| BeOne Medicines Ltd. Sponsored ADR | ONC | 1 | PHASE1 | BGB-16673 |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Dupilumab |
| Enanta Pharmaceuticals, Inc. | ENTA | 1 | PHASE1 | EDP-978 |